Genco Alfredo, Ienca Roberta, Ernesti Ilaria, Maselli Roberta, Casella Giovanni, Bresciani Sabrina, Mariani Stefania, Soricelli Emanuele, Baglio Giovanni, Lorenzo Michele, Monti Massimo
Department of Surgical Sciences, Surgical Endoscopy Unit, La Sapienza University of Rome, Rome, Italy.
Department of Experimental Medicine-Medical Physiopathology, Food Science and Endocrinology Section, Sapienza University of Rome, Rome, Italy.
Obes Surg. 2018 Dec;28(12):3733-3737. doi: 10.1007/s11695-018-3448-9.
It is generally accepted that the efficacy with an intragastric balloon decreases after the first 4 months of treatment. Aim of this study is to evaluate if the association of a very low-calorie ketogenic diet (VLCKD) can improve the results in terms of weight loss parameters and co-morbidities, as compared to usually prescribed low-calorie diet (LCD).
For the present study (January 2016-June 2017), 80 patients (20 M/60 F, mean age 37.8 ± 6.1 years; excess weight 56 ± 10 kg; mean BMI 37.2 ± 3.8 kg/m) underwent Orbera positioning. After 4 months, they were randomized into two groups according to the type of treatment: group A (Bioenterics intragastric balloon - Orbera + VLCKD) (n = 40), and group B (Orbera + LCD) (n = 40).
All patients completed the study with good adherence to diet therapy treatment allocation. After the 6-month treatment period, at time of Orbera removal, mean weight loss was 19 kg and 12 kg in groups A and B respectively (p < 0.05). Mean BMI was 28.9 ± 2.8 and 31.6 ± 3.1 kg/m (p < 0.05), and %EWL was 33.1 ± 3.3 and 21.1 ± 2.9 (p < 0.05) in groups A and B respectively. During the last 2 months in group A, the mean weight loss was 8 kg, while in Group B, the main weight loss was 3 kg (p < 0.001). The VLCKD treatment induced a more significant reduction of major comorbidities related to metabolic syndrome.
This study clearly indicates the efficacy of the prescription of very low-calorie ketogenic diet improving the efficacy of intragastric balloon positioning.
人们普遍认为,胃内球囊治疗4个月后疗效会降低。本研究的目的是评估与通常规定的低热量饮食(LCD)相比,极低热量生酮饮食(VLCKD)联合使用是否能在体重减轻参数和合并症方面改善治疗效果。
在本研究(2016年1月至2017年6月)中,80例患者(20例男性/60例女性,平均年龄37.8±6.1岁;超重56±10kg;平均BMI 37.2±3.8kg/m²)接受了奥贝拉胃内球囊置入。4个月后,根据治疗类型将他们随机分为两组:A组(生物肠内胃内球囊 - 奥贝拉 + VLCKD)(n = 40)和B组(奥贝拉 + LCD)(n = 40)。
所有患者均完成了研究,对饮食治疗分配的依从性良好。在6个月的治疗期后,即取出奥贝拉胃内球囊时,A组和B组的平均体重减轻分别为19kg和12kg(p < 0.05)。A组和B组的平均BMI分别为28.9±2.8和31.6±3.1kg/m²(p < 0.05),%EWL分别为33.1±3.3和21.1±2.9(p < 0.05)。在A组的最后2个月中,平均体重减轻为8kg,而在B组中,主要体重减轻为3kg(p < 0.001)。VLCKD治疗使与代谢综合征相关的主要合并症得到更显著的减轻。
本研究清楚地表明,极低热量生酮饮食的处方可提高胃内球囊置入的疗效。